Team:Westminster
From 2012.igem.org
(Difference between revisions)
(140 intermediate revisions not shown) | |||
Line 1: | Line 1: | ||
- | |||
- | |||
<html> | <html> | ||
+ | |||
<head> | <head> | ||
- | <style type="text/css"> | + | |
- | + | <meta http-equiv="content-type" content="text/php; charset=utf-8" /> | |
- | + | ||
- | + | <style type="text/css"> | |
- | + | @import url 'http://yui.yahooapis.com/2.9.0/build/reset/reset-min.css'; | |
- | + | ul { | |
- | + | list-style: none; | |
- | + | } | |
- | + | body { | |
- | } | + | font-family: "HelveticaNeue-Light", "Helvetica Neue Light", "Helvetica Neue", Helvetica, Arial, "Lucida Grande", sans-serif; |
- | + | font-weight: 300; | |
- | + | /* background: url("http://www.westminsterigem.com/files/theme/body-bg.png") repeat #ffffff;*/ | |
- | + | background-color:#FFF; | |
- | + | color: #666666; | |
- | + | ||
- | } | + | } |
- | div# | + | h1 { |
- | + | color: #ff0000; | |
- | } | + | font-size: 18pt; |
- | + | margin-bottom: 0.5em; | |
- | + | } | |
- | + | p { | |
- | } | + | |
- | + | } | |
- | + | a { | |
- | + | ||
- | + | } | |
- | + | #p-logo { | |
- | } | + | background: #444444; |
- | ul#navigation | + | } |
- | + | div#top-section, | |
- | } | + | div#content { |
- | ul#navigation > li | + | box-shadow: 0px 0px 17px -4px #666666; |
- | + | padding:0px; | |
- | + | margin-top:0px; | |
- | } | + | |
- | ul#navigation | + | } |
- | + | div#wrapper { | |
- | + | position: relative; | |
- | + | width: 100%; | |
- | + | font-size: 12pt; | |
- | + | margin: 0 auto; | |
- | } | + | background: #ffffff; |
- | ul#navigation a.navlink:hover { | + | background-attachment: url('https://static.igem.org/mediawiki/2012/2/2e/Bg-tumours.png'); |
- | + | background-repeat: no-repeat; | |
- | + | ||
- | + | padding:0px; | |
- | } | + | margin-top:0px; |
- | div#footer-box { | + | top:0px; |
- | + | ||
- | } | + | } |
- | </style> | + | div#header { |
+ | height: 120px; | ||
+ | width: 100%; | ||
+ | background-color:#000; | ||
+ | background: url('https://static.igem.org/mediawiki/2012/2/2e/Bg-tumours.png'); | ||
+ | background-repeat: no-repeat; | ||
+ | z-index:10; | ||
+ | position:relative; | ||
+ | top:0px; | ||
+ | left:0px; | ||
+ | } | ||
+ | div#header div#logo { | ||
+ | position: relative; | ||
+ | width: 260px; | ||
+ | right:10px; | ||
+ | top:-9px; | ||
+ | float:right; | ||
+ | |||
+ | margin-bottom: 0px; | ||
+ | /* | ||
+ | height: 0px; | ||
+ | margin: 0 auto;*/ | ||
+ | } | ||
+ | div#header div#logo a { | ||
+ | float:left; | ||
+ | display:block; | ||
+ | margin-left:10px; | ||
+ | |||
+ | } | ||
+ | |||
+ | |||
+ | div#navigation { | ||
+ | width: 850px; | ||
+ | height: 27px; | ||
+ | background:rgba(0,0,0,.5); | ||
+ | float:left; | ||
+ | position:relative; | ||
+ | top:54px; | ||
+ | } | ||
+ | ul#navigation-list { | ||
+ | height: 27px; | ||
+ | line-height: 27px; | ||
+ | overflow: auto; | ||
+ | } | ||
+ | ul#navigation-list > li { | ||
+ | float: left; | ||
+ | margin-top:-5px; | ||
+ | } | ||
+ | ul#navigation-list > li > ul { | ||
+ | position: absolute; | ||
+ | display: none; | ||
+ | background: #000000; | ||
+ | z-index: 100000; | ||
+ | } | ||
+ | ul#navigation-list > li > ul.submenu { | ||
+ | margin: 0; | ||
+ | } | ||
+ | ul#navigation-list > li > ul.submenu li { | ||
+ | padding: 2px 0px; | ||
+ | } | ||
+ | ul#navigation-list a.navlink { | ||
+ | color: #ffffff; | ||
+ | font-weight: normal; | ||
+ | display: block; | ||
+ | padding: 0px 10px; | ||
+ | text-decoration: none; | ||
+ | } | ||
+ | ul#navigation-list a.navlink.active, | ||
+ | ul#navigation-list a.navlink:hover { | ||
+ | color: #ff0000; | ||
+ | } | ||
+ | div#home-main-image { | ||
+ | text-align: center; | ||
+ | background-color: #410000; | ||
+ | height:475px; | ||
+ | border-bottom:1px #000 solid; | ||
+ | } | ||
+ | div#the-content { | ||
+ | position:relative; | ||
+ | top:-19px; | ||
+ | |||
+ | } | ||
+ | div#home-main-image img { | ||
+ | /*width: 885px; | ||
+ | height: 300px; | ||
+ | margin-bottom: 20px; | ||
+ | border-radius: 20px; | ||
+ | */ | ||
+ | } | ||
+ | div.text-box { | ||
+ | background: #444444; | ||
+ | color: #ffffff; | ||
+ | padding: 15px 20px; | ||
+ | border-radius: 10px; | ||
+ | |||
+ | } | ||
+ | div#footer-box { | ||
+ | border-radius: 0 0 5px 5px; | ||
+ | } | ||
+ | #bodyContent { | ||
+ | } | ||
+ | #three-column | ||
+ | { | ||
+ | margin:0 auto; | ||
+ | width:850px; | ||
+ | margin-top:50px; | ||
+ | |||
+ | } | ||
+ | |||
+ | .col | ||
+ | { | ||
+ | text-align:justify; float:left; margin:5px; | ||
+ | } | ||
+ | .col h1 | ||
+ | { | ||
+ | font-size:14px; | ||
+ | color:#000; | ||
+ | |||
+ | } | ||
+ | /* hide native rubbish*/ | ||
+ | #top-section {display:none; position:absolute; left:0px; top:-200px;} | ||
+ | #top-section a { color:#FFF; } | ||
+ | .firstHeading {display:none; position:absolute; left:0px; top:-200px;} | ||
+ | .annoying-gap { | ||
+ | padding:0px; | ||
+ | margin:0px; | ||
+ | line-height:0; | ||
+ | } | ||
+ | |||
+ | #contentSub, #siteSub {display:none;} | ||
+ | |||
+ | #control-btn | ||
+ | { | ||
+ | |||
+ | width: 20px; | ||
+ | height: 20px; | ||
+ | position:absolute; | ||
+ | top:0px; | ||
+ | left:5px; | ||
+ | |||
+ | line-height: 0px; | ||
+ | |||
+ | |||
+ | } | ||
+ | .btn-cog { | ||
+ | background: url('https://static.igem.org/mediawiki/2012/d/d4/Control-panel-sml.png') #000 no-repeat 2px 2px; | ||
+ | } | ||
+ | .btn-close { | ||
+ | background: url('https://static.igem.org/mediawiki/2012/d/d0/Close-btn.png') #000 no-repeat 2px 2px; | ||
+ | } | ||
+ | .right-menu li a, .left-menu li a {background: none} | ||
+ | </style> | ||
+ | |||
+ | <script type="text/javascript" src="http://code.jquery.com/jquery-1.8.2.min.js"></script> | ||
+ | <script type="text/javascript"> | ||
+ | $('document').ready(function() { | ||
+ | |||
+ | // menu | ||
+ | $('li.submenu-holder').hover(function() { | ||
+ | $(this).children('ul.submenu').stop(true).fadeIn('fast'); | ||
+ | }, function() { | ||
+ | $(this).children('ul.submenu').stop(true).fadeOut('fast'); | ||
+ | }); | ||
+ | |||
+ | // hide standard team basics | ||
+ | $('#top-section').hide(); | ||
+ | $('#bodyContent p:first').addClass("annoying-gap"); | ||
+ | |||
+ | |||
+ | $('#control-btn').click( function(){ | ||
+ | |||
+ | if ($('#control-btn').hasClass("btn-cog")) | ||
+ | { | ||
+ | showTopMenu(); | ||
+ | $('#control-btn').animate({left: "-20px"}); | ||
+ | $('#control-btn').addClass("btn-close"); | ||
+ | $('#control-btn').removeClass("btn-cog"); | ||
+ | } else | ||
+ | { | ||
+ | hideTopMenu(); | ||
+ | $('#control-btn').animate({left: "0px"}); | ||
+ | $('#control-btn').addClass("btn-cog"); | ||
+ | $('#control-btn').removeClass("btn-close"); | ||
+ | } | ||
+ | }); | ||
+ | |||
+ | }); | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | var $bar; | ||
+ | function hideTopMenu() | ||
+ | { | ||
+ | $bar.slideUp('fast'); | ||
+ | |||
+ | } | ||
+ | function showTopMenu() | ||
+ | { | ||
+ | if ($bar==null) | ||
+ | { | ||
+ | $bar = $("#top-section").clone(); | ||
+ | $($bar.find("#search-controls")).remove(); | ||
+ | $($bar.find("#p-logo")).remove(); | ||
+ | $("#wrapper").prepend($bar); | ||
+ | $bar.css("position", "absolute"); | ||
+ | $bar.css("top", "0px"); | ||
+ | $bar.css("left", "0px"); | ||
+ | $bar.css("background", "none"); | ||
+ | $bar.css("background", "rgba(0,0,0,.5)"); | ||
+ | $bar.css("height", "20px"); | ||
+ | $bar.css("border", "none"); | ||
+ | $bar.css("z-index", "100"); | ||
+ | $bar.css("color", "#000"); | ||
+ | |||
+ | |||
+ | } | ||
+ | $bar.slideDown('fast'); | ||
+ | |||
+ | $('#control-btn').mouseover( function(){ | ||
+ | |||
+ | }); | ||
+ | } | ||
+ | </script> | ||
</head> | </head> | ||
<body> | <body> | ||
- | < | + | <div id="wrapper"> |
- | + | ||
- | + | <div id="header"> | |
- | + | <div id="control-btn" class="btn-cog"></div> | |
- | + | ||
- | + | <div id="navigation"> | |
- | + | <ul id="navigation-list"> | |
- | + | <li><a href="https://2012.igem.org/Team:Westminster" class="navlink active">Home</a></li> | |
- | + | <li><a href="https://2012.igem.org/Team:Westminster/Team" class="navlink">Team</a></li> | |
- | + | <li class="submenu-holder"> | |
- | </ul> | + | <a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink">Project</a> |
+ | |||
+ | <ul class="submenu"> | ||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink">Overview</a></li> | ||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Problem"class="navlink">The Problem</a></li> | ||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Experiments"class="navlink">Experiments</a></li> | ||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Protocols"class="navlink">Protocols</a></li> | ||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Results"class="navlink">Results</a></li> | ||
+ | |||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | ||
+ | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li> | ||
+ | |||
+ | |||
+ | </ul> | ||
+ | </li> | ||
+ | <li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li> | ||
+ | <li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li> | ||
+ | <li><a href="https://2012.igem.org/Team:Westminster/Outreach"class="navlink">Outreach</a></li> | ||
+ | <li><a href="https://2012.igem.org/Team:Westminster/Judging"class="navlink">Judging Criteria</a></li> | ||
+ | |||
+ | |||
+ | <li><a href="https://2012.igem.org/Team:Westminster/Attributions"class="navlink">Attributions</a></li> | ||
+ | </ul><!-- #navigation-list --> | ||
+ | </div><!-- #navigation --> | ||
+ | <div id="logo"> | ||
+ | <a href="http://www.igem.org" title="iGEM homepage"><img src="https://static.igem.org/mediawiki/igem.org/d/dc/Igem-small-white.png" alt="iGEM logo" width="55" height="44" /></a> | ||
+ | <a href="https://2012.igem.org/Team:Westminster"> | ||
+ | <img src="https://static.igem.org/mediawiki/2012/a/ae/Logo-white.png" alt="iSTEM - intelligent synthetic tumour eliminating machine" width="172" height="66" title="iSTEM - intelligent synthetic tumour eliminating machine" /> | ||
+ | </a> | ||
+ | </div><!-- #logo --> | ||
+ | </div><!-- #header --> | ||
+ | |||
+ | <div id="the-content"> | ||
+ | <div id="home-main-image"> | ||
+ | <!--img src="https://static.igem.org/mediawiki/2012/4/4d/Westminster_team.png" alt="Welcome" title="Welcome to our home!" /---> | ||
+ | <div style="float:left;padding-left:30px;padding-top:50px; width:380px"> | ||
+ | <h1 style="text-align:left;border:none; color:#fff; position:relative;bottom:0px; left:0px; margin:0px; padding:0px 0px 20px 0px;">Fighting cancer from the inside out</h1> | ||
+ | <div style="color:white; text-align:justify;">Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.<br/><br/> | ||
+ | The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.</div> | ||
+ | |||
+ | |||
+ | </div> | ||
+ | <div style="float:left; width:500px; padding-left:50px; padding-top:150px; text-align:center"> | ||
+ | <img src="https://static.igem.org/mediawiki/2012/8/8a/Tumor.png" alt="Tumor" width="218" height="179" /> | ||
+ | </div> | ||
+ | |||
+ | </div><!-- #home-main-image --> | ||
+ | |||
+ | |||
+ | |||
+ | <div id="three-column"> | ||
+ | |||
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/d/d7/IntegratedDNALogo.jpg" width="146" height="61"/> | ||
+ | </div> | ||
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/b/b9/GeneiousLogo.jpg" width="136" height="54"/> | ||
+ | </div> | ||
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/a/af/MathWorksLogo.jpg" width="202" height="40"/> | ||
+ | </div> | ||
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/8/8e/AutodeskLogo.jpg" width="161" height="41"/> | ||
+ | </div> | ||
+ | <div class="col"> | ||
+ | <img src="https://static.igem.org/mediawiki/igem.org/c/c7/UniversityWestminsterLogo.jpg"/> | ||
+ | </div> | ||
+ | |||
+ | </div> | ||
+ | |||
+ | </div><!-- #the-content --> | ||
+ | |||
+ | </div><!-- #wrapper --> | ||
+ | |||
+ | |||
</body> | </body> | ||
- | |||
- | + | </html> | |
- | + | [[iGEM 2013]] | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Latest revision as of 18:58, 9 August 2013
Fighting cancer from the inside out
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.
The Westminster iGEM 2012 team aims to combat cancer recurrence by using one key feature of CSCs – increased Aldehyde Dehydrogenase (ALDH) activity. We have used the promoters of 4 different ALDH isoforms present in aggressive forms of cancer to design 3 constucts that will allow us to identify, isolate and eliminate CSC, offering a novel tool for the study of these cells and a potential new anti-cancer therapy for the future.